News

Symic Bio, a biopharmaceutical company developing novel matrix regulators, today announced that Ken Horne, Chief Executive Officer, will present an overview of the company pipeline at the Ladenburg Thalmann 2017 Healthcare Conference in New York…

Symic Bio, a biopharmaceutical company developing novel matrix regulators, today announced the treatment of the first patient in the MODIFY2 Phase 2 clinical trial investigating SB-061 for pain management in mild-to-moderate osteoarthritis of the knee. The initiation of the 12-week, multicenter, double-blinded trial of approximately 60 patients follows previously announced Phase 1/2a clinical results supporting the safety, tolerability and intended mechanism of action of SB-061…

Symic Bio, a biopharmaceutical company developing novel matrix regulator therapeutics, announced today the appointment of Glenn Prestwich, Ph.D., as Executive Vice President of Chemistry. Dr. Prestwich, Presidential Professor of Medicinal Chemistry at the University of Utah and former member of the Symic Bio Scientific Advisory Board, will assume a direct executive role in the advancement of the company’s platform of clinical-stage therapeutics and in the expansion of its pipeline…

Symic Bio, a biopharmaceutical company developing novel matrix regulator therapeutics, today announced the successful completion of a $30 million Series B financing and provided a program update regarding lead program SB-030. The Series B financing involved participation of all current major investors as well as new investor HEDA Ventures…

Symic Bio, a biopharmaceutical company developing novel matrix regulator therapeutics, today announced topline results from the Phase 1/2a MODIFY-OA trial of SB-061, an intra-articular treatment for osteoarthritis of the knee. SB-061 was shown to be safe and very well-tolerated with no drug-related serious adverse events and a very low rate of local adverse events (4.1 percent)…

Symic Bio, a biopharmaceutical company focused on matrix biology that is developing a new category of therapeutics, today announced that Rinko Ghosh, President and Chief Business Officer, will present an overview of current programs at the upcoming 11th Annual BIO-Europe Spring Conference…

Symic Bio, a biopharmaceutical company focused on matrix biology that is developing a new category of therapeutics, announced today the completion of enrollment for the SHIELD clinical trial of SB-030 in peripheral artery disease. The trial will evaluate the safety and efficacy of SB-030, a locally administered single-use therapeutic, in the reduction of restenosis following angioplasty…

Symic Bio, a clinical-stage biotech company that is developing a new category of therapeutics focused on matrix biology, today announced that Ken Horne, Chief Executive Officer, will present at the BIO CEO & Investor Conference 2017 and the Cowen Health Care Conference…

Symic Bio, a biopharmaceutical company focused on matrix biology that is developing a new category of therapeutics, today announced the appointment of Scott W. Morrison to its Board of Directors. Mr. Morrison was U.S. Life Sciences Leader at Ernst & Young LLP until his retirement in December 2015…

Symic Bio, a clinical stage biopharmaceutical company focused on matrix biology developing a new category of therapeutics, today announced that Ken Horne, Chief Executive Officer, will participate in the 2017 East/West CEO Conference on a panel entitled “Global Perspectives on Funding and Innovation”…

Symic Bio, a clinical stage biopharmaceutical company focused on extracellular matrix biology developing a new category of therapeutics, today announced that Ken Horne, Chief Executive Officer, will present an overview of the company pipeline and progress at the upcoming Piper Jaffray Healthcare Conference…

Symic Bio, a clinical stage biopharmaceutical company developing a new category of therapeutics focused on extracellular matrix biology, announced today the completion of enrollment for its Phase 1/2a MODIFY-OA clinical trial of SB-061 in the treatment of osteoarthritis of the knee. Top-line results from the trial are expected to be announced in the first half of 2017…

Symic Bio, a clinical-stage biopharmaceutical company developing a new category of therapeutics focused on extracellular matrix biology, today announced that Rinko Ghosh, President and Chief Business Officer, will present at the 22nd Annual BIO Europe Conference in Cologne. The presentation will take place within the autoimmune/inflammation track…

Symic Bio, a clinical stage biopharmaceutical company developing a new category of therapeutics focused on extracellular matrix biology, today announced that Morten Karsdal, Ph.D., has been appointed as a member of the company’s Scientific Advisory Board…

Symic Bio, a clinical stage biotherapeutics company developing novel compounds that target and affect the extracellular matrix, today announced that Thomas N. Wight, Ph.D., Director of the Matrix Biology Program at the Benaroya Research Institute and Affiliate Professor of Pathology at the University of Washington, has been appointed as a member of the company’s Scientific Advisory Board…

Symic, a clinical stage biotherapeutics company developing therapies inspired by naturally occurring molecules of the extracellular matrix, today announced that Ken Horne, Chief Executive Officer, will present at the BioCentury NewsMakers in the Biotech Industry Conference…

Symic, a clinical stage biotherapeutics company developing novel compounds that target and affect the extracellular matrix, today announced that Carolyn Bertozzi, Ph.D., has been appointed as a member of the company’s Scientific Advisory Board…

Symic, a clinical stage biotherapeutics company developing multiple compounds that target and affect the extracellular matrix, today announced the appointment of Manish Anand as Vice President of Regulatory Affairs and Quality. Mr. Anand will lead the company’s regulatory strategy, global filings and quality efforts…

Symic, a clinical stage biotherapeutics company developing multiple compounds that target and affect the extracellular matrix (ECM), today announced the treatment of the first patient in the MODIFY-OA Clinical Trial (Study to Measure the Safety and Efficacy Outcome after Intra-articular Delivery of SB-061 versus Control in Symptomatic Osteoarthritis Patients) investigating SB-061, a novel and proprietary treatment specifically developed for acute management of osteoarthritis (OA) pain…

Symic, a clinical stage biotherapeutics company developing novel compounds that target and affect the extracellular matrix, today announced that Alyssa Panitch, Ph.D., one of the founders of the company and an inventor of Symic’s technology, has been appointed to chair the company’s Scientific Advisory Board…

Symic, a clinical stage biotherapeutics company developing novel compounds that target and affect the extracellular matrix, today announced that Ken Horne, Chief Executive Officer, will present at the Boston Biotech Conferences Boston CEO Conference as part of the session “Next Generation Biotech CEOs and Board Members”…

Symic, a clinical stage biotherapeutics company developing multiple compounds that target and affect the extracellular matrix, today announced that Jocelyn Jackson, Chief Financial Officer, will present at BioEquity Europe 2016 in Copenhagen and the Bay Area Biotech Forum in San Francisco…

Symic, a clinical-stage biotherapeutics company developing multiple compounds that target the extracellular matrix, today announced the appointment of Kathleen Gogas, Ph.D., as Vice President of Preclinical Development. Dr. Gogas will lead the company’s research efforts in preclinical pharmacology and oversee IND enabling research…

Symic, a clinical-stage biotherapeutics company developing multiple compounds that target and affect the extracellular matrix (ECM), today announced that Rinko Ghosh, President and Chief Business Officer, will present at the BIO Europe Spring Conference in Stockholm…

Symic, a clinical-stage biotherapeutics company developing multiple compounds that target and affect the extracellular matrix (ECM), today announced that Ken Horne, Chief Executive Officer, will present at the 13th Annual BIO Asia International Conference in Tokyo…

Symic, a clinical-stage biotherapeutics company developing multiple compounds that target and affect the extracellular matrix (ECM), today announced that Ken Horne, Chief Executive Officer, will present at the 23rd Annual BioCentury Future Leaders in the Biotech Industry Conference in New York…

Symic, a clinical-stage biotherapeutics company developing multiple compounds that target and affect the extracellular matrix (ECM), today announced the appointment of Rinko Ghosh as President and Chief Business Officer…

Symic, a clinical-stage biotherapeutics company developing multiple compounds that target and affect the extracellular matrix (ECM), today announced that it continues to fortify the patent protection covering its proteoglycan-based therapeutic platform with U.S. Patent No 9,217,016, which will be issued on Dec. 22, 2015. This patent covers SB-061, a compound that mimics the protective proteoglycan, aggrecan, to reduce cartilage degradation and pain in patients with osteoarthritis (OA)…

Symic, a clinical-stage biotherapeutics company developing multiple compounds that target and affect the extracellular matrix (ECM), today announced the appointment of Seema Kantak, Ph.D., as Chief Scientific Officer…

Symic, a clinical-stage biotherapeutics company developing multiple compounds that target and affect the extracellular matrix (ECM), today announced that it has secured $25 million in a Series A-2 financing to advance the company’s pipeline, including its lead candidates SB-030 and SB-061. The financing was led by Lilly Ventures and includes the participation by all existing major investors, as well as several new investors. This new funding brings the total capital raised by Symic to over $43 million since being founded in 2012…

Symic Bio, a clinical-stage biotherapeutics company developing multiple compounds that target and affect the extracellular matrix (ECM), today announced the selection of SB-061 as the company’s first osteoarthritis clinical candidate. In preclinical studies, SB-061 was shown to reduce pain and cartilage degradation in models of osteoarthritis. SB-061, which will be administered as an intra-articular injection, is designed to prevent the degradation of cartilage by mimicking the protective effect of the proteoglycan aggrecan…

Symic Bio, a clinical-stage biotherapeutics company developing multiple compounds that target the extracellular matrix (ECM), today announced the appointment of Kamal Egodage, Ph.D., MBA, as Vice President of Development & Manufacturing and Grace Wong-Sarad as Vice President and Controller…

Symic Bio, a clinical-stage biotherapeutics platform company developing compounds that target the extracellular matrix (ECM), today announced the treatment of the first patient in its Phase 1/2 clinical Study in Humans to Investigate the Efficacy and Safety of Luminal SB-030 Delivery in Peripheral Artery Disease (SHIELD Trial). The study will evaluate the safety and efficacy of SB-030 (previously SBCV-030), a locally applied, single-use treatment for the reduction of neointimal hyperplasia resulting from the vascular injury following percutaneous transluminal angioplasty (PTA)…

Platform therapeutic company Symic Bio, Inc. (“Symic”) announced today that it has received a $1.5M Phase II SBIR grant from the National Institutes of Health (NIH) to further develop its therapeutic agent to reduce arteriovenous fistula (AVF) failures, a significant unmet clinical need in end stage renal disease (ESRD) patients undergoing hemodialysis…

Symic Bio announced today the selection of SBCV-030 as the clinical candidate for the company’s first vascular program. In preclinical studies SBCV-030 inhibits the scarring response that occurs when a vessel is injured. Initially, clinical indications where acute injuries are caused by vascular surgery or percutaneous intervention will be pursued. SBCV-030 will be delivered locally at the time of the procedure. SBCV-030 will be first investigated in peripheral arterial disease, or PAD, a disease that affects approximately eight million Americans according to the Center for Disease Control, or CDC…

Symic Bio announced today the appointment of Barbara Yanni and William J. Newell to its board of directors. Mr. Newell is the CEO of Sutro Biopharma, Inc. which has entered into a strategic collaboration and acquisition option with Celgene regarding their therapeutic technology platform. Ms. Yanni retired in 2014 from Merck & Co., Inc. where she was most recently Vice President and Chief Licensing Officer…

Symic Bio today announced a strategic alliance with Nordic Bioscience A/S to focus on the clinical development of Symic’s osteoarthritis (OA) program. Nordic Bioscience (Copenhagen, Denmark) is a world-‐‐renowned pharmaceutical development organization…

Symic Bio announced today that the company has secured $15 million in Series A financing. This financing will support the company’s ongoing development of its novel therapeutics, and advancement of its two lead programs into clinical trials…